Summary
Abstract To address the significant challenges of immunotherapy for solid tumors, Absco Therapeutics (AbscoTx) has developed a novel intratumoral delivery system utilizing the Oncolymer™ platform. The need for new effective approaches to deliver therapeutics into tumors and activate the potential of immunotherapy for solid tumors is particularly evident in microsatellite instability-low (MSI-low) cancers, such as most colorectal carcinomas where immune-checkpoint inhibitors show efficacy in less than 5% of patients. The Oncolymer platform can revolutionize tumor therapy by enabling sustained,
